What is the price of Clarus Therapeutics Holdings, Inc. (CRXTQ)

The price of Clarus Therapeutics Holdings, Inc. (CRXTQ) is $0.0014

What is the market cap of Clarus Therapeutics Holdings, Inc. (CRXTQ)

The market cap of Clarus Therapeutics Holdings, Inc. (CRXTQ) is $72.83K

Clarus Therapeutics Holdings, Inc. (CRXTQ) Operating Margin

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

Year	Operating Margin	Change
Not enough data for the provided dates.

Year

Operating Margin

Change

Not enough data for the provided dates.

Company	Operating Margin	Operating Margin Difference	Country
Eli Lilly and Company LLY.US	45.87%	-	US
Johnson & Johnson JNJ.US	26.81%	-	US
AbbVie Inc. ABBV.US	27.60%	-	US
Roche Holding AG RO.SW	26.59%	-	CH
Merck & Co., Inc. MRK.US	27.59%	-	US

Company

Operating Margin

Operating Margin Difference

Country